332 related articles for article (PubMed ID: 26848151)
21. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
Lowery MA; Kelsen DP; Capanu M; Smith SC; Lee JW; Stadler ZK; Moore MJ; Kindler HL; Golan T; Segal A; Maynard H; Hollywood E; Moynahan M; Salo-Mullen EE; Do RKG; Chen AP; Yu KH; Tang LH; O'Reilly EM
Eur J Cancer; 2018 Jan; 89():19-26. PubMed ID: 29223478
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Gabrielson A; Tesfaye AA; Marshall JL; Pishvaian MJ; Smaglo B; Jha R; Dorsch-Vogel K; Wang H; He AR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1073-9. PubMed ID: 26449224
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.
Pishvaian MJ; Slack RS; Jiang W; He AR; Hwang JJ; Hankin A; Dorsch-Vogel K; Kukadiya D; Weiner LM; Marshall JL; Brody JR
Cancer; 2018 Jun; 124(11):2337-2346. PubMed ID: 29579325
[TBL] [Abstract][Full Text] [Related]
24. Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.
Mehta MP; Wang D; Wang F; Kleinberg L; Brade A; Robins HI; Turaka A; Leahy T; Medina D; Xiong H; Mostafa NM; Dunbar M; Zhu M; Qian J; Holen K; Giranda V; Curran WJ
J Neurooncol; 2015 Apr; 122(2):409-17. PubMed ID: 25682091
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
Arun BK; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bell-McGuinn KM; Bach BA; Kundu MG; Ratajczak CK; Maag D; Diéras V
Eur J Cancer; 2021 Sep; 154():35-45. PubMed ID: 34243076
[TBL] [Abstract][Full Text] [Related]
26. Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
Werner TL; Sachdev J; Swisher EM; Gutierrez M; Kittaneh M; Stein MN; Xiong H; Dunbar M; Sullivan D; Komarnitsky P; McKee M; Tan AR
Cancer Med; 2018 Jun; 7(6):2360-2369. PubMed ID: 29733524
[TBL] [Abstract][Full Text] [Related]
27. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
Reiss KA; Herman JM; Armstrong D; Zahurak M; Fyles A; Brade A; Milosevic M; Dawson LA; Scardina A; Fischer P; Hacker-Prietz A; Kinders RJ; Wang L; Chen A; Temkin S; Horiba N; Stayner LA; Siu LL; Azad NS
Gynecol Oncol; 2017 Mar; 144(3):486-490. PubMed ID: 28109627
[TBL] [Abstract][Full Text] [Related]
28. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.
Cecchini M; Walther Z; Wei W; Hafez N; Pilat MJ; Boerner SA; Durecki DE; Eder JP; Schalper KA; Chen AP; LoRusso P
Cancer Res Commun; 2023 Jun; 3(6):1113-1117. PubMed ID: 37377610
[TBL] [Abstract][Full Text] [Related]
29. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Rugo HS; Olopade OI; DeMichele A; Yau C; van 't Veer LJ; Buxton MB; Hogarth M; Hylton NM; Paoloni M; Perlmutter J; Symmans WF; Yee D; Chien AJ; Wallace AM; Kaplan HG; Boughey JC; Haddad TC; Albain KS; Liu MC; Isaacs C; Khan QJ; Lang JE; Viscusi RK; Pusztai L; Moulder SL; Chui SY; Kemmer KA; Elias AD; Edmiston KK; Euhus DM; Haley BB; Nanda R; Northfelt DW; Tripathy D; Wood WC; Ewing C; Schwab R; Lyandres J; Davis SE; Hirst GL; Sanil A; Berry DA; Esserman LJ;
N Engl J Med; 2016 Jul; 375(1):23-34. PubMed ID: 27406347
[TBL] [Abstract][Full Text] [Related]
30. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
[TBL] [Abstract][Full Text] [Related]
31. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
32. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
Kummar S; Oza AM; Fleming GF; Sullivan DM; Gandara DR; Naughton MJ; Villalona-Calero MA; Morgan RJ; Szabo PM; Youn A; Chen AP; Ji J; Allen DE; Lih CJ; Mehaffey MG; Walsh WD; McGregor PM; Steinberg SM; Williams PM; Kinders RJ; Conley BA; Simon RM; Doroshow JH
Clin Cancer Res; 2015 Apr; 21(7):1574-82. PubMed ID: 25589624
[TBL] [Abstract][Full Text] [Related]
33. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
34. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.
Kummar S; Wade JL; Oza AM; Sullivan D; Chen AP; Gandara DR; Ji J; Kinders RJ; Wang L; Allen D; Coyne GO; Steinberg SM; Doroshow JH
Invest New Drugs; 2016 Jun; 34(3):355-63. PubMed ID: 26996385
[TBL] [Abstract][Full Text] [Related]
36. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.
Duan W; Gao L; Zhao W; Leon M; Sadee W; Webb A; Resnick K; Wu X; Ramaswamy B; Cohn DE; Shapiro C; Andreassen PR; Otterson GA; Villalona-Calero MA
Transl Res; 2013 Mar; 161(3):156-64. PubMed ID: 23063585
[TBL] [Abstract][Full Text] [Related]
37. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.
Gojo I; Beumer JH; Pratz KW; McDevitt MA; Baer MR; Blackford AL; Smith BD; Gore SD; Carraway HE; Showel MM; Levis MJ; Dezern AE; Gladstone DE; Ji JJ; Wang L; Kinders RJ; Pouquet M; Ali-Walbi I; Rudek MA; Poh W; Herman JG; Karnitz LM; Kaufmann SH; Chen A; Karp JE
Clin Cancer Res; 2017 Feb; 23(3):697-706. PubMed ID: 27503200
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
Jelinek MJ; Foster NR; Zoroufy AJ; Schwartz GK; Munster PN; Seiwert TY; de Souza JA; Vokes EE
Oral Oncol; 2021 Mar; 114():105171. PubMed ID: 33513474
[TBL] [Abstract][Full Text] [Related]
39. Veliparib for the treatment of ovarian cancer.
Bogliolo S; Cassani C; Dominoni M; Musacchi V; Venturini PL; Spinillo A; Ferrero S; Gardella B
Expert Opin Investig Drugs; 2016; 25(3):367-74. PubMed ID: 26807493
[TBL] [Abstract][Full Text] [Related]
40. A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors.
LaRose M; Connolly RM; O'Sullivan CC; Velcheti V; Vilimas R; Gano K; Bates SE; Pommier Y; Thomas A
Oncologist; 2023 May; 28(5):460-e298. PubMed ID: 37010988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]